Inherited variants in the DPYD gene can increase the risk of life-threatening toxicity from fluoropyrimidine-based chemotherapies, yet screening remains inconsistent across care settings.
Researchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
A study reports that dual epigenetic markers in cell-free DNA achieved 95% diagnostic accuracy for stage I colorectal cancer, outperforming conventional liquid biopsy methods.
ClearNote Health has launched an enhanced pancreatic cancer test, reporting 82.6% sensitivity and 97.5% specificity in high-risk patients using a multianalyte, multiomic blood-based approach.
Read More
The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.
Read More
Guardant Health will provide up to 100 free Shield blood tests per organization to support colorectal cancer screening events and outreach during Colorectal Cancer Awareness Month in March.
Read More
The CLIA-certified facility offers functional precision medicine testing that analyzes live tumor cells against FDA-approved therapies within 10 days.
Read More
Hims & Hers Health is now offering GRAIL’s Galleri multi-cancer blood test through its digital health platform, expanding access to screening for more than 50 cancer types, including those lacking established protocols.
Read More
Johns Hopkins researchers have developed a liquid biopsy that detects early-stage lung and breast cancers by measuring DNA methylation variation, showing high accuracy in a study published in Clinical Cancer Research.
Read More
Researchers at La Trobe University have developed a single-use test strip that detects cancer-related microRNAs in blood plasma at concentrations up to 1,000 times lower than current methods.
Read More
New Labcorp survey of 152 oncologists reveals 89% expect care to become more complex within three years, while digital integration and coverage barriers persist.
Read More
Ambry Genetics supported a new study evaluating 6,718 PALB2 gene variants using MAVEs, advancing risk assessment for hereditary breast and pancreatic cancer.
Read More
GRAIL has submitted an FDA premarket approval application for its Galleri multi-cancer early detection test, supported by data from more than 25,000 participants in US and UK clinical trials.
Read More
A new study found the assay detected immunotherapy response in advanced cancer patients a median of 23 days after treatment—over five months earlier than imaging.
Read More
Valley Diagnostics has secured exclusive global rights to develop point-of-care lateral flow tests for prostate cancer, lung cancer, and animal diseases, with product rollout planned for 2026.
Read More
A real-world study of 111,080 participants found the Galleri multi-cancer blood test achieved a 0.91% cancer detection rate and 87% accuracy in predicting tumor origin.
Read More
Researchers at Mass General Brigham have developed a blood test that predicts tarlatamab response in small cell lung cancer, showing 85% sensitivity and 100% specificity.
Read More
The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.
Read More